Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

MannKind Corporation - Common Stock (NQ:MNKD)

5.560 +0.020 (+0.36%)
Streaming Delayed Price Updated: 9:58 AM EDT, Sep 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 497,747
Open 5.500
Bid (Size) 5.550 (6)
Ask (Size) 5.560 (11)
Prev. Close 5.540
Today's Range 5.440 - 5.560
52wk Range 3.381 - 7.630
Shares Outstanding 264,305,532
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
MannKind Lands A Price-Target Hike After Partner United Therapeutics Reports Strong Lung Drug Trial Results
Via Stocktwits
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga

Performance

YTD
-15.8%
-15.8%
1 Month
+58.0%
+58.0%
3 Month
+27.2%
+27.2%
6 Month
+11.4%
+11.4%
1 Year
-8.9%
-8.9%

More News

Read More
There are notable gap-ups and gap-downs in today's session.
Via Chartmill
Tuesday's pre-market session: top gainers and losers
Via Chartmill
MannKind, United Therapeutics Expand Agreement To Develop A Second Investigational Molecule Together
Via Stocktwits
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)
From Brodsky & Smith LLC
Via GlobeNewswire
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
MannKind Announces $500M Financing Agreement With Blackstone After Q2 Revenue Miss: Retail Believes Stock Is ‘Ridiculously Undervalued’
Via Stocktwits
Earnings Scheduled For August 6, 2025
Via Benzinga
MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy
From MannKind
Via GlobeNewswire
MannKind’s $360M scPharma Deal Splits Analysts — Retail Traders Call It ‘Bizarro Territory’ But Stay Bullish
Via Stocktwits
MannKind, Backed By Blackstone, Expands Cardiorenal Focus With $360 Million Deal
Via Benzinga
A Look Ahead: MannKind's Earnings Forecast
Via Benzinga
MannKind Corporation to Acquire scPharmaceuticals: More Details Inside
Via Stocktwits
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
From MannKind
Via GlobeNewswire
MannKind (MNKD) Q2 Revenue Rises 6%
Via The Motley Fool
Topics Intellectual Property World Trade
MannKind Corp (NASDAQ:MNKD) Q2 2025 Earnings Miss Estimates, Shares Drop 3.8% in Pre-Market
Via Chartmill
Topics Earnings
MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement
From MannKind
Via GlobeNewswire
MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update
From MannKind
Via GlobeNewswire
MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025
From MannKind
Via GlobeNewswire
Top 3 Health Care Stocks That May Rocket Higher This Quarter
Via Benzinga
MannKind to Highlight Data from Recent Pediatric and Adult Studies of Inhaled Insulin (Afrezza®) at American Diabetes Association’s 85th Scientific Sessions in Chicago, June 20-23
From MannKind
Via GlobeNewswire
MannKind to Present at Upcoming Investor Conferences
From MannKind
Via GlobeNewswire
MannKind Corporation Reports First Quarter 2025 Financial Results and Provides Business Update
From MannKind
Via GlobeNewswire

Frequently Asked Questions

Is MannKind Corporation - Common Stock publicly traded?
Yes, MannKind Corporation - Common Stock is publicly traded.
What exchange does MannKind Corporation - Common Stock trade on?
MannKind Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for MannKind Corporation - Common Stock?
The ticker symbol for MannKind Corporation - Common Stock is MNKD on the Nasdaq Stock Market
What is the current price of MannKind Corporation - Common Stock?
The current price of MannKind Corporation - Common Stock is 5.560
When was MannKind Corporation - Common Stock last traded?
The last trade of MannKind Corporation - Common Stock was at 09/08/25 09:58 AM ET
What is the market capitalization of MannKind Corporation - Common Stock?
The market capitalization of MannKind Corporation - Common Stock is 1.47B
How many shares of MannKind Corporation - Common Stock are outstanding?
MannKind Corporation - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.